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Abstract: Synthetic biology is an emerging area of research that combines the investigative nature of biology with the
constructive nature of engineering. Despite the field being in its infancy, it has already aided the development of a
myriad of industrially and pharmaceutically useful compounds, devices and therapies and is now being applied within
the field of regenerative medicine. By combining synthetic biology with regenerative medicine, the engineering of cells
and organisms offers potential avenues for applications in tissue engineering, bioprocessing, biomaterial and scaffold
development, stem cell therapies and even gene therapies. This review aims to discuss how synthetic biology has
been applied within these distinct areas of regenerative medicine, the challenges it faces and any future possibilities
this exciting new field may hold.1 Introduction
Since its inception, the field of synthetic biology has endeavoured
to make the engineering of biology more reliable, efficient and
predictable with the aim of expanding the range of possible
biological functions for research and therapeutic applications [1].
It seeks to solve existing problems by constructing new and
improved models as opposed to relying on analysis and
observation alone [2], thereby distinguishing itself from traditional
biological approaches. It is because of this that synthetic biology
has greatly influenced the advancement of the field of regenerative
medicine. Some of the key milestones can be seen in Fig. 1 [3–34].
Regenerative medicine is an interdisciplinary area of research and
clinical applications that facilitates the repair, replacement and
regeneration of cells, tissues or organs to restore impaired function
resulting from trauma, ageing, congenital defects or disease [35].
Unlike the transplantation and replacement therapies that were
previously used, regenerative medicine uses a combination of
several existing and newly emerging converging technological
concepts. Traditional methods in regenerative medicine have relied
on utilising the natural, evolved behaviour of human cells, thereby
supporting and stimulating the body’s own self-healing capability.
When combined with synthetic biology, the potential to improve
our ability to help those in clinical need greatly increases [36] and
novel solutions are presented to help combat several of the
challenges currently faced within the field [37].
Such challenges include (i) the need for intercellular
communication and spatiotemporal coordination within three-
dimensional tissue-engineered constructs [38, 39]; (ii) the limited
proliferative capability and plasticity of adult stem cells and the
need to achieve adequate cell numbers for therapeutic applications
through extensive in vitro expansion [40, 41]; (iii) the nonspecific
pleiotropic effects of cytokines, extracellular matrix (ECM)
molecules and growth factors on lineage fate determination and
cellular differentiation [42]; and finally (iv) the safety issues
associated with the genetic modification of human stem cells and
the use of viral vectors and recombinant DNA [43]. These
clinical challenges have also been critically examined in detail
elsewhere [37].
With these challenges in mind, synthetic biology can be applied to
several areas within regenerative medicine, including cell, tissue and
organ transplantation, tissue engineering, bioprocessing and control,
biomaterials and scaffolds, stem cell therapies, and gene therapies.This review aims to examine how synthetic biology has affected
these various aspects of regenerative medicine, how it could be
applied or improved in the future, and also some of the challenges
faced within this promising new field.2 Synthetic biology and tissue engineering
Given the unique ability of stem cells to provide trophic support and
replace dying cells [44], their manipulation is one of the main
methods used when approaching challenges within regenerative
medicine. Examples of this include the addition of stem cells to
damaged or diseased tissue to promote healthy tissue growth, ex
corpora manufacture of new organs from stem cells followed by
transplantation, the addition of mesenchymal stem cells (MSCs) to
secrete cytokines, trophic factors and growth factors to signal for
regeneration in endogenous cells; and finally repairing tissues
following pharmacological intervention by stimulating the
differentiation of stem cells or the division of healthy tissue
surrounding a damaged site [45].
Due to this, tissue engineering is one of the main areas within
regenerative medicine that has greatly improved since the
implementation of synthetic biology, as shown in Fig. 2. Where
the cross-over of scientific and technological advances, methods
and techniques such as gene circuits for easier and enhanced
manipulation of cells and cell signalling has and continues to
impact upon the field of regenerative medicine and tissue
engineering [6, 23, 25, 27–29]. Within this last decade, however,
one of the most notable breakthroughs in tissue engineering was
achieved by Baiguera et al. (2010). Through using an optimised
detergent-enzymatic method (25 cycles) to decellularise cadaver
tracheal tissue, they were successful in creating a bioengineered
trachea that was structurally and mechanically similar to native
trachea, and contained angiogenic factors that exerted
chemo-active and pro-angiogenic properties. This structure was
obtained within three weeks as opposed to the typical three
months, thereby allowing the development of clinically
functioning, fully in vivo tissue engineered airway replacements
that can be obtained within a clinically useful time [23, 46].
In saying this, research is still underway to develop improved
human tissue structures through the use of novel state-of-the art
technologies and methods, for instance three-dimensional (3D)
printing, 3D-biofabrication approaches (a combination of1
Fig. 1 Brief timeline of some of the key milestones in synthetic biology with regards to regenerative medicine and the emerging healthcare industry
Fig. 2 Rises in synthetic biology and genetic engineering (pre-2000) and synthetic biology (post-2000) (green), regenerative medicine (blue) and tissue
engineering in regenerative medicine (yellow) as shown by the number of publications released. The term synthetic biology as used today under current
definition was created around early 2000 therefore this term was used for searching post-2000 literature, but pre-2000, the terms genetic engineering and
synthetic biology were used to be more representative of the emerging field. Graph was obtained using PubMed online search database, a search was
conducted using YYY, XXX, where YYY represents the search terms synthetic biology and genetic engineering (pre-2000), synthetic biology (post-2000),
regenerative medicine, tissue engineering regenerative medicine. XXX represents the range of publication release dates, from 1960 to 20163D-bioplotting and thermally-assisted forming) [47, 48], and the
generation of orgainoids by bioreactor-assisted self-assembly
methods [49].3 Materials and scaffolds
Another aspect of synthetic biology that has greatly aided the field of
tissue engineering is the development of synthetic biomaterials and
scaffolds.
Biomaterials play a pivotal role in modern day regenerative
medicine and tissue engineering approaches. The natural or
synthetic polymers used to produce the biomaterials and scaffolds
act as designable and biochemical milieus [50] that elicit specific
cellular functions [51] and facilitate the attachment, guidance, and2 This is an opendifferentiation of cells in vivo [52–54]. Being able to manipulate
both the physical and chemical properties of the scaffolds allows
the customisation and innovation not offered by naturally
occurring materials. The guidance provided promotes the
restoration of structure and function of damaged or dysfunctional
tissues in both cell-based and acellular therapies [50], the
development of a biomineralised scaffold for the repair of bone
and other hard tissues is a prime example of this [55].
By implementing synthetic biology into the design and creation of
biomaterials and scaffolds, it has led to the development of an array
of biologically compatible synthetic materials which, when
compared to naturally occurring materials, significantly reduce the
risk of carrying biological pathogens or contaminants into the host
[56]. Such innovative biomaterials, developed in the last decade,
include novel synthetic peptide-based biomaterial scaffolds [56],Eng. Biol., pp. 1–6
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interactive biohybrid materials [57–59] and the development of
semi-synthetic ECMs from covalently cross-linked biodegradable
hydrogels [60]. This semi-synthetic ECM is designed to allow the
inclusion of the specific biological cues required to simulate the
complexity of the ECM of a given tissue. Prestwich [60]
suggested that the development of such a scaffold offers a
manufacturable, flexible, highly reproducible, affordable, and Food
and Drug Administration (FDA)-approvable vehicle for cell
expansion and differentiation in a 3D environment, in theory
making it ideal for clinical applications. Although these
semi-synthetic ECMs are currently still in the research and
developing stages of the development pipeline, some are currently
being used as research tools for 3D culture of stem cells, primary
human cells and orthotropic tumour xenografts. They are also
being marketed as products for veterinary wound care and bone
repair [61]. In addition to this, in 2015 the first synthetic in situ
cross-linkable hyaluronic acid (HA) hydrogel, similar to the one
used to create the semi-synthetic ECM, entered clinical trials for
the treatment of HIV-induced lipoatrophy [62], thereby showing
promise for the use of synthetic or semi-synthetic scaffolds within
regenerative medicine.
However, even though several promising concepts have been
established, some challenges still exist. Our inability to reprogram
stem cells into uniform populations with no unwanted potency and
to predictably control endogenous cells is restricting the progress
of the field [63, 64]. Synthetic biology has the potential to
overcome these limitations and could, in future, facilitate true
tissue regeneration.4 Bioprocessing and control
Bioprocessing and its control have come to play a pivotal role in both
the synthetic biology and regenerative medicine fields. Especially
with the development of large scale bioreactors, cryopreservation
of cells [65] and other exciting technologies, such as single-use
cellular expansion technologies [66] and serum-free suspension
cultures [67], which are discussed in detail elsewhere [66].
Bioprocessing aides the development of biopharmaceuticals,
for instance therapeutic proteins, polysaccharides, vaccines and
diagnostic tools as well as the development of antibiotics [68]. In
the context of regenerative medicine, the cell itself is the final
treatment product from the bioprocess rather than the means by
which to produce a desired substance or outcome [66]. This means
that the product itself is the bioprocess, suggesting that anything
and everything within the process could affect the overall outcome
of the product, thereby making the bioprocessing of mammalian
cells extremely difficult.
This being said, synthetic biology has been shown to improve
the overall stability of bioprocessing. This can be achieved by
providing an increased robustness during bioreactor cultivations,
improved fermentation characteristics and product yields and also
the design and application of termination signals [69]. Termination
signals are stop signals that are found in the transcribed regions of
DNA templates and specify the end of translation of transcription
of DNA. With regards to synthetic biology, if the applied
termination signal functions successfully, it could become an asset
with regards to bioprocessing, but if it fails to effectively terminate
transcription, it could lead to major problems in plasmid-based
genetic devices. In response to this, Mairhofer et al. [69]
conducted research into combining a synthetic T7 termination
signal with two transcriptional terminators (rrnBT1 and T7) and
were able to increase the termination efficiency from the 80%
given by the native T7 terminator, to 99%. It is research such as
this, which can lead to an increase in the stability of bioprocesses
and instil confidence in their use within fields like regenerative
medicine, where safety and certainty in the product is of the
utmost concern.
Another way in which synthetic biology has aided bioprocessing
is through the use of biosensors. Genetically-encoded biosensors, for
instance are pieces of DNA that contain the instructions for a
biosensor circuit [70]. They have the ability to monitor cellularEng. Biol., pp. 1–6
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resulting in a gain in productivity whilst ensuring robustness and
reproducibility in the overall bioprocess [70]. Although the use of
synthetic biosensors shows promising results, there exist several
concerns with regard to their safety. Schmidt and Pei [71] state
that there is the possibility of misuse, dual use and a risk of
biosecurity, they claim that there is a lack of efficient toxicological
assessment methods available to evaluate the synthetically derived
biosensors. In comparison to this, Bhatia and Chugh [72] state that
synthetic biology has the potential to address the biosafety fears
surrounding biosensors, and is currently researching into devising
‘self-destruction’ or tracking strategies within microorganisms. If
these strategies are proven successful and their safety is
guaranteed, in future, similar systems could be incorporated into
mammalian processes.
It is believed, if synthetic biosensors are to progress within
research, one of the major challenges must be addressed. That is,
that a robust and efficient biosensor must be developed that
contains a regulatory pathway that governs use and safety of the
product [72].5 Stem cell therapies
Once synthetic biology was proven to be applicable to eukaryotic
cells, the focus began to shift towards adding new tools to the
current available technologies. These tools include the modification
of signalling pathways related to disease, novel gene level
intervention (gene therapy) and cell therapies [73]. Cell therapies
are a primary area within regenerative medicine, especially when
combined with the use of stem cells. Various stem cell types
[including umbilical-cord, embryonic, mesenchymal, adipose, cord
blood, limbal and induced pluripotent stem cells (iPSCs)] have
already been used in treatments for a myriad of conditions, with
some successfully reaching clinical trials [74–76]. Conditions
include bone marrow transplantation for leukaemia, other blood
diseases such as Fanconi anaemia and various cancers. In addition,
blindness through corneal damage or disease such as macular
degeneration, bone and cartilage repair, heart attack, stroke and
critical limb ischaemia [74, 77].
Some therapies that incorporate stem cells include the healing of
burns and wounds [78], and cancer based immunotherapy [79].
With regards to wound healing, stem cell therapy offers a
treatment for chronic skin wounds such as diabetic and venous
ulcers, as well as deep acute wounds. At this current point in time,
none of the technological approaches are able to regenerate skin
appendages, most notably hair follicles and sweat glands. In
future, by incorporating synthetic biology and the availability of
adult stem cells and iPSCs from the patient, there’s the possibility
of generating these structures without risking immune rejection.
This could then potentially form the basis of new therapies that
address the current limitations [78] and producing a treatment
more beneficial for the patient.
Synthetic biology can also be implemented in cellular engineering
and genome editing of host cells, as shown in the cell-based cancer
immunotherapy research, where a patient’s T cells were engineered
and used as therapeutic agents. In this instance, synthetic biology
can be utilised to improve the efficacy of cell-based cancer
therapeutics, through the development and application of synthetic
sensors, switches and circuits [66]. This could potentially reduce
the time and cost of manufacturing, thereby making it highly
desirable for clinical applications. Chakravarti and Wong [79]
claim that by applying synthetic biology, cell-based therapies can
become safer and more powerful. As a result of this, in future,
both regenerative medicine and the healthcare sector are
anticipated to benefit greatly from synthetically modified cells, in
that they will have use of cells that have the ability to discriminate
between cell states, integrate multiple inputs and respond
appropriately to combat diseases and injuries. It is thought that
with improved tools and well-characterised bio-parts, synthetic
biology has the potential to revolutionise therapeutic research and
increase our understanding of disease progression [80]. Potentially3Commons
allowing synthetic biologists to overcome many if not all of the
obstacles faced by stem cell therapies and advance the field
towards clinical applications.6 Gene therapies
With synthetic biology’s remarkable ability to construct functional
biological devices from well-characterised components, it has
since become possible to engineer synthetic control networks and
signalling cascades that can program cell morphology [81],
metabolic behaviour [82, 83] and therapeutic interventions [84]
with high precision [85]. By applying synthetic therapeutic gene
circuits in mammalian cells to control specific signalling networks,
it presents the possibility of improved therapeutic treatments for
numerous diseases and disorders [85]. These range from metabolic
disorders such as obesity [86], Type 1 [87] and Type 2 [86]
diabetes, to cancer [88] and immunological diseases.
A significant challenge faced by synthetic biology is to integrate
these synthetic circuits into the desired location within a host
genome, whilst maintaining the genetic integrity of both the circuit
and the host [80]. The CRISPR-Cas9 system [89], derived from a
bacterial defence mechanism, is a breakthrough genome editing
technology that has guided synthetic biologists to take steps
towards accomplishing this. With its use, researchers can introduce
correct mutations into the genomes of cells and organisms with a
level of ease and proficiency that was not previously possible [90].
It is because of this that CRISPR-Cas9 offers unparalleled
opportunities in fighting genetic disease, the targeted modification
of whole genomes, in vivo models for drug discovery [88] as well
in cell therapy and regenerative medicine [90, 91]. Given the rapid
pace of the fields development, the technology is continuously
adapting and improving. Current advancements continue to make
its use easier and faster, thereby yielding significant benefits for
both preclinical and clinical use.
Despite this, although CRISPR-Cas9 is considered the gold
standard technology, especially when compared to other
genome-editing technologies [92, 93], it too experiences some
limitations with regards to greater understanding of off-target
effects and optimisation in application that must be dealt with
before being viable for altering the human germline for preventive
purposes. Heidari et al. [91] state that these limitations are brought
on by our limited understanding of genetics. As such, if
technologies such as CRISPR are to reach their full potential and
be translated to the clinic, we must first gain a better
understanding of genetic disorders, particularly those involving
multiple genes and the genetic interventions required, and then
find methods to surpass the pre-existing translational barriers
surrounding gene therapies. Current translational barriers centre
primarily upon scale-up of manufacture as well as quantity and
quality of donor samples for therapeutic targeting in some
instances. With the advances of DNA foundries and continuing
improvements in efficiency and scale for developing synthetic
tools and more accessible DNA synthesis, synthetic biology has
the potential to offer novel manufacturing solutions that cross-over
to overcome translational barriers in other emerging fields such as
gene therapies in the near future.7 Current challenges
Stem cell research has always experienced ethical, legal, and social
complications [94, 95]. When synthetic biology is added to that,
you then include the issue of using genetic modification, which in
itself has its own set of social and ethical problems. As a result of
this, when a cell that is used in regenerative medicine is
genetically modified, it will be considered a new product. This
suggests that before gaining approval from various health boards,
for instance the European Medicines Agency (EMA) or the US
FDA, the product will have to undergo another round of extensive
characterisation to prove that no other region in its genome has
been altered. Consequently, in addition to placing genetic burden4 This is an openon the cell, it will also have to undergo extra physical stress,
which can greatly affect the phenotype of the cell.
Having said this, guaranteeing safety and gaining public approval
are some of the major challenges faced by synthetic biology today.
As such, extensive characterisation is just one way of ensuring
confidence in the end product. Another way of combating the
challenges faced is by finding alternative methods for treatments.
For example, one of the ongoing issues faced within regenerative
medicine is the use of embryonic stem cells (ESCs) and their
derivation from human embryonic blastocysts. Research has been
conducted to consider the use of induced pluripotent stem cells
(iPSCs) as an alternative to ESCs, as they overcome two of
the ESCs primary problems; immune rejection following
transplantation and ethical concerns as they are derived from adult
cells [64, 78]. Having said this, using iPSCs also presents
insurmountable risk, especially when it entails the genetic
modification of both donor and host cells, generated by the
transfection of a viral vector following iPSC transplantation
[44, 96], which has parallels with further application of synthetic
biology in the field. It is for this reason, that entry into the clinic
is slow as much work must be done to guarantee the safety of
their use as iPSCs are being incorporated into preclinical and
clinical applications, such as for age-related macular degeneration
(AMD) [76].
Another key aspect of synthetic biology is to guarantee
reproducibility of systems across various applications and cell
types, thereby improving its engineering and translational
capability. Currently, when the circuits are introduced across
different organisms and cell lines, synthetic biology experiences
complications with variable circuit efficacy. This could potentially
be overcome by focusing on the use of standardised circuit
elements that have already been proven to function in multiple
bacterial or mammalian hosts. Doing this could increase the ease
of manufacturing as well as ensure that therapies reach patients
much faster [80].8 Conclusions
Synthetic biology is a field that is still in its infancy, but is
continuously expanding into new and exciting areas of research. It
has already aided the development of a myriad of industrially and
pharmaceutically useful compounds, devices and therapies and is
now helping the field of regenerative medicine to progress. Tissue
engineering, materials and scaffolds development, bioprocessing
control, stem cell and gene therapies are all areas that have greatly
benefited from its contribution, and are all areas in which synthetic
biology can truly make a difference in future.
Despite its many achievements, it still faces several challenges
which many researchers are continuously trying to overcome. As
synthetic biology continues to advance, there are still numerous
avenues it could pursue within regenerative medicine. One such
avenue is to implement synthetic biology more into mammalian
cells, making the therapy or product a step closer to being
clinically viable. This would greatly benefit the emerging
healthcare industry, where mammalian products are severely
lacking. Another avenue that could be explored in future is the use
of synthetic biosensors to improve the manufacturing process of
gene therapies. An innovation such as this would help researchers
meet future clinical demand for gene therapies, whilst still
maintaining the natural phenotype and efficacy of the cells.9 References
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